Oncology News and Research RSS Feed - Oncology News and Research Twitter

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Twenty years data analysis shows patients treated with HIPEC may have improved survival rates

Meaningful long-term survival is possible for selected patients suffering from advanced cancer of the abdomen when treated with cytoreductive surgery with Hyperthermic IntraPeritoneal Chemotherapy, or HIPEC, according to a first-of-its-size analysis by physicians at Wake Forest Baptist Medical Center. [More]

Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

Three Johns Hopkins University School of Medicine researchers have been awarded two-year grants for their work on potential treatments for diabetes, Novo Nordisk announced this month. Of the 110 initial submissions to the new Novo Nordisk Diabetes and Obesity Biologics Science Forum Program, only four projects were funded, three of which are led by Johns Hopkins researchers. They are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., Ph.D. [More]
Viewpoints: Obamacare still has more challenges; GOP needs to help make law work; census change is not Obama's decision

Viewpoints: Obamacare still has more challenges; GOP needs to help make law work; census change is not Obama's decision

The first open enrollment period under the Affordable Care Act ended this week with roughly 7.5 million people obtaining policies through the new state insurance exchanges, including more than 1.3 million at Covered California. [More]

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Men who show signs of chronic inflammation in non-cancerous prostate tissue may have nearly twice the risk of actually having prostate cancer than those with no inflammation, according to results of a new study led by researchers from the Johns Hopkins Kimmel Cancer Center. [More]

Skin docs prescribe costlier drugs after free samples

In other news, panels recommend a costly hepatitis C drug for the sickest patients, and cancer doctors will compare the value of costly cancer drugs. [More]

XBiotech announces results from Phase I/II oncology study

XBiotech is announcing that results from its Phase I/II oncology study conducted at MD Anderson Cancer Center in Houston, TX were published today in Lancet Oncology. The featured article describes the outcome in 52 advanced cancer patients treated with Xilonix™, XBiotech's novel, non-cytotoxic, anti-tumor therapy. [More]
Study: Chronic inflammation associated with aggressive prostate cancer

Study: Chronic inflammation associated with aggressive prostate cancer

The presence of chronic inflammation in benign prostate tissue was associated with high-grade, or aggressive, prostate cancer, and this association was found even in those with low prostate-specific antigen (PSA) levels, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. [More]
B1/Cdk1 protein which plays key role in cell division also boosts power of mitochondrial activity

B1/Cdk1 protein which plays key role in cell division also boosts power of mitochondrial activity

​An international team led by researchers at UC Davis has shown that the cyclin B1/Cdk1 protein complex, which plays a key role in cell division, also boosts the mitochondrial activity to power that process. [More]
FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

Actavis plc and Forest Laboratories, Inc. today announced that they have each received a request for additional information from the Federal Trade Commission ("FTC") in connection with Actavis' pending acquisition of Forest. [More]
Actavis to purchase four currently marketed products from Akorn

Actavis to purchase four currently marketed products from Akorn

Actavis plc, a leading global specialty pharmaceutical company, today announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development [More]

Researchers recommend early colorectal cancer screening guidelines for cervical cancer survivors

Researchers at the University of Texas Medical Branch at Galveston are the first to recommend that young women treated with radiation for cervical cancer should begin colorectal cancer screening earlier than traditionally recommended. [More]

John Hopkins researchers create novel optical imaging equipment for use on SARRP research platform

Researchers from John Hopkins University have created an innovative piece of optical imaging equipment for use on-board the Xstrahl Small Animal Radiation Research Platform. [More]

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

CANCER RESEARCH UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]
Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer Ingelheim announced today that the US Food and Drug Administration (FDA) and the European Commission have granted volasertib* 'orphan drug designation' for the treatment of patients with acute myeloid leukaemia (AML). [More]

Researchers create clinical trial for patients with advanced lung cancer

Cancer Research UK is partnering with pharmaceutical companies AstraZeneca and Pfizer to create a pioneering clinical trial for patients with advanced lung cancer - marking a new era of research into personalised medicines to treat cancer. [More]

Top performing oncology drugs at risk of losing patent rights by 2022

After a period of relative stability, a glut of patent expiries is just five years away for the oncology market, according to pharmaceutical analyst Datamonitor Healthcare. [More]

Professor from INRS receives NIH grant to explore biomedical potential in field of oncology

Professor Nicolas Doucet of the Centre INRS-Institut Armand-Frappier has just received a research grant from the National Institutes of Health (NIH) in the amount of nearly US$600,000. The 5-year grant is to pursue cutting-edge research in the workings of tiny proteins called RNases and to explore their biomedical potential in the field of oncology as well as in inflammation and asthma. [More]
Epirus Biopharmaceuticals to merge with Zalicus

Epirus Biopharmaceuticals to merge with Zalicus

Zalicus Inc., and Epirus Biopharmaceuticals, Inc., a Boston-based biopharmaceutical company focused on the global development and commercialization of biosimilar monoclonal antibodies, announced today that they have entered into a definitive agreement under which Epirus will merge with a wholly-owned subsidiary of Zalicus in an all-stock transaction. [More]

NICE recommends FIRMAGON for treating advanced hormone-dependent prostate cancer in adults with spinal metastases

The National Institute for Health and Care Excellence (NICE) today issued its Final Appraisal Determination (FAD) recommending FIRMAGON (degarelix) as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. [More]

Cardiologists, cancer experts join forces to establish Cardio-Oncology Clinic at Mount Sinai Hospital

Cardiologists and cancer experts at The Mount Sinai Hospital have joined forces to establish its first Cardio-Oncology Clinic at The Tisch Cancer Institute at The Mount Sinai Hospital. [More]